Try our Advanced Search for more refined results
BioNTech SE et al v. CureVac SE
Case Number:
2:23-cv-00222
Court:
Nature of Suit:
Judge:
Firms
- Duane Morris
- Groombridge Wu
- Kaufman & Canoles
- Marshall Gerstein
- McGuireWoods
- Paul Hastings
- Saul Ewing
- Spotts Fain
- White & Case
- Willkie Farr
Companies
Sectors & Industries:
-
August 20, 2024
Vax Patent Battles Heat Up As Attention On Pandemic Wanes
It's been over four years since clinical trials began for COVID-19 vaccines, and while the shots have helped the pandemic recede, the lucrative technology has spurred numerous patent suits, many of which are still in the early stages. Here's a look at some of the key cases in the U.S.
-
April 25, 2024
CureVac, Acuitas Reach Deal In COVID Vax Patent Dispute
CureVac SE told a Virginia federal judge Thursday that it has reached a settlement to resolve Acuitas Therapeutics Inc.'s lawsuit inventorship credit on patents related to lipid nanoparticle technology used to develop the blockbuster Pfizer and BioNTech COVID-19 vaccine.
-
April 15, 2024
Hold This COVID Vax Patent Case, Judge Recommends
One of the suits over Pfizer's blockbuster COVID-19 vaccine hit a snag in Virginia federal court Friday when a judge recommended pausing the case to wait for a ruling in a related dispute over patent ownership involving one of BioNTech's other partners.
-
May 19, 2023
CureVac Lobs Infringement Counterclaims At BioNTech, Pfizer
CureVac on Friday accused BioNTech and Pfizer of infringing nine of its patents covering COVID-19 technology, lodging counterclaims in the pharmaceutical companies' case, which was recently transferred from Massachusetts to Virginia federal court.